2216 Stock Overview
A medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Broncus Holding Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.53 |
52 Week High | HK$1.09 |
52 Week Low | HK$0.46 |
Beta | 0.91 |
11 Month Change | -7.02% |
3 Month Change | -13.11% |
1 Year Change | -50.00% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -96.47% |
Recent News & Updates
Recent updates
We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully
Mar 21Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans
Nov 30Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?
May 31Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth
Feb 27An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued
Dec 06Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers
Sep 04Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation
Jun 21Shareholder Returns
2216 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | -1.9% | 3.8% | 2.2% |
1Y | -50.0% | -45.4% | -1.6% |
Return vs Industry: 2216 underperformed the Hong Kong Medical Equipment industry which returned -45.4% over the past year.
Return vs Market: 2216 underperformed the Hong Kong Market which returned -1.6% over the past year.
Price Volatility
2216 volatility | |
---|---|
2216 Average Weekly Movement | 4.9% |
Medical Equipment Industry Average Movement | 6.8% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.5% |
10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2216's share price has been volatile over the past 3 months.
Volatility Over Time: 2216's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 308 | Hong Xu | www.broncus.com |
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); RF-II, transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Ablation System for the treatment of COPD; H-Marker, treatment for lung cancer/lung nodules; disposable nebulizing micro-catheter for endoscope used for accurate anti-inflammation, local hemostasis, phlegm reduction and elimination, staining location, and local anesthesia; and BroncTru, a disposable transbronchoscopic puncture dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPoint ATV System, an archimedes system.
Broncus Holding Corporation Fundamentals Summary
2216 fundamental statistics | |
---|---|
Market cap | HK$279.41m |
Earnings (TTM) | -HK$218.80m |
Revenue (TTM) | HK$79.88m |
3.5x
P/S Ratio-1.3x
P/E RatioIs 2216 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2216 income statement (TTM) | |
---|---|
Revenue | US$10.26m |
Cost of Revenue | US$3.03m |
Gross Profit | US$7.23m |
Other Expenses | US$35.32m |
Earnings | -US$28.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.053 |
Gross Margin | 70.47% |
Net Profit Margin | -273.92% |
Debt/Equity Ratio | 0.009% |
How did 2216 perform over the long term?
See historical performance and comparison